#RadioligandTherapy can feel overwhelming if you don’t know what to expect.
There is a special NEN patient guide to help you prepare.
👉Available in 15 languages
✅Download for free: incalliance.org/net-info-pac...
#LetsTalkAboutNETs

📢Today is #WorldRadiotheranosticsDay! Let’s spread awareness about the impact of a field that combines therapy and diagnostics to revolutionize cancer treatment.
✅Download INCA’s free patient guide on #RadioligandTherapy, in 15 languages: incalliance.org/net-info-pac...
#LetsTalkAboutNETs

📢#WorldRadiotheranosticsDay is on March 31st. #RadioligandTherapy plays a crucial role in NEN treatment and maintaining quality of life during the patient journey.
✅INCA has developed a free patient guide on #RadioligandTherapy in 15 languages: incalliance.org/net-info-pac...
#LetsTalkAboutNETs

Lutetium Lu 177 Vipivotide Tetraxetan Remains Effective After Sipuleucel-T in mCRPC | OncLive Lutetium Lu 177 vipivotide tetraxetan was active after treatment with sipuleucel-T in real-world mCRPC.

Real-world data show lutetium Lu 177 vipivotide tetraxetan maintains strong activity after sipuleucel-T, with median OS ~19.8 months and robust PSA responses #ProstateCancer #GUonc #mCRPC #RadioligandTherapy #Oncology
Read more ➡️ www.onclive.com/view/lutetiu...

Starting radioligand therapy can feel overwhelming.
The #RadioligandTherapy NETInfo factsheet answers your questions and helps you get prepared — in your own language.
🌍15 languages supported.
✅Download now: incalliance.org/net-info-pac...
#LetsTalkAboutNETs #NeuroendocrineNeoplasms

Knowledge is power.
The multilingual #NETInfo factsheet on #RadioligandTherapy helps you understand the treatment and feel ready for it.
Available in 15 languages.
✅Download in your language: incalliance.org/net-info-pac...
#LetsTalkAboutNETs

Novartis、米ノースカロライナ州に旗艦製造ハブ建設へ：バイオ医薬品からxRNA技術まで一括生産体制を強化 | STELLANEWS.LIFE Novartisはノースカロライナ州に新たな製造ハブを建設し、生物製剤、無菌包装、固形製剤に加え、細胞・遺伝子治療やxRNA技術も視野に入れた生産体制を拡大。2030年までに700名の新規雇用を創出予定。

Novartis to Build Flagship Manufacturing Hub in North Carolina

🔗 Full article: stellanews.life/technology_c...

#Novartis #PharmaManufacturing #Biologics #xRNA #CellTherapy #RadioligandTherapy #Biotech #NorthCarolina #SupplyChain #USInvestment

Facing radioligand therapy? You’re not alone.
👉This #NETInfo factsheet on #RadioligandTherapy is designed for neuroendocrine tumor patients to guide you step by step through your treatment journey.
🌍Available in 15 languages.
✅Download now: incalliance.org/net-info-pac...
#LetsTalkAboutNETs

RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...

Emmanuel Seront, MD, PhD, discusses the Phase II RENALUT trial of 177Lu-PSMA-617 in metastatic ccRCC post-TKI/IO therapy, exploring PSMA-targeted radioligand therapy as a new option for resistant disease

🎥 buff.ly/dLhijGf

#KidneyCancer #KCSM #CTSM #TrialUpdate #RadioligandTherapy #RadOnc #ESMO25

Starting radioligand therapy can feel overwhelming.
📌The #RadioligandTherapy #NETInfo factsheet answers your questions and helps you get prepared — in your own language.
🌍Available in 15 languages.
✅Download in your language: incalliance.org/net-info-pac...
#LetsTalkAboutNETs

Sanofi, Orano cue up filings for GEP-NET radioligand therapy Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.

#Sanofi has said its #radioligandtherapy (RLT) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) hit all its objectives in a phase 2 study, setting up possible regulatory filings.

Theranostics 2.0: The Expanding Clinical Applications of Radioligand Therapy Beyond Oncology—A Narrative Review - Premier Science Radioligand therapy, Non-oncologic theranostics, Nanotheranostics, 68ga-dotatate vascular imaging, ai-assisted dosimetry

premierscience.com/pjbs-25-1047/

#theranostics #radioligandtherapy #oncology

Are you preparing for radioligand therapy?
INCA’s #NETInfo factsheet on #RadioligandTherapy helps you prepare with confidence knowing what to expect in your everyday life.
• Available in 15 languages.
Download now incalliance.org/net-info-pac...
#LetsTalkAboutNETs

Are you scheduled for radioligand therapy? You do not have to be stressed.
✅Download the #NETInfo factsheet on #RadioligandTherapy to be prepared and stress-free.
🌍Available in 15 languages: incalliance.org/net-info-pac...
#LetsTalkAboutNETs

Facing radioligand therapy? You’re not alone.
The new #NETInfo factsheet on #RadioligandTHerapy is designed to guide neuroendocrine tumor patients step by step through their treatment journey.
🌍Available in 15 languages.
Download now incalliance.org/net-info-pac...
#LetsTalkAboutNETs

📢New to radioligand therapy? Prepare with confidence with the new #NETInfo factsheet from INCA in your language: incalliance.org/net-info-pac...
📌This medically-vetted factsheet on #RadioligandTherapy answers your questions and helps you get prepared.
#LetsTalkAboutNETs

Starting radioligand therapy can feel overwhelming.
👉INCA provides a medically-vetted factsheet on #RadioligandTherapy that answers your questions and helps you get prepared.
🌍Available in 15 languages: incalliance.org/net-info-pac...
#LetsTalkAboutNETs

Starting radioligand therapy can feel overwhelming for neuroendocrine cancer patients.
📢INCA launched a NEW #NETInfo factsheet on #RadioligandTherapy designed to support NEN patients.
✅Available in 15 languages to download from #NETInfo Pack: incalliance.org/net-info-pac...
#LetsTalkAboutNETs

Over 100 #NuclearMedicine sites worldwide are now Level 1 certified in #Theranostics via #EARL’s Centres of Excellence programme! 🎉

Thank you for setting a new global standard in #RadioligandTherapy.

Level 2 is coming—stay tuned!

👉 earl.eanm.org/theranostics/

🎙️ New on #OncologyBytes from #COA2025

Dr. Jeffrey Scott on building oncology GPOs, scaling value-based care, and why theranostics are the next big revenue wave.
📺 Watch: youtu.be/eEOZyLmjqC0

📲 🌐 Learn more at: oncoassist.com

#ValueBasedCare #CommunityOncology #RadioligandTherapy #Oncoassist

March is #ProstateCancerAwarenessMonth in the UK📣

Omid Yazdanpanah, MD explores the potential of #radioligandtherapy combined with #androgen receptor pathway inhibitors (ARPIs) for #metastatic #castrationresistant #prostatecancer (mCRPC)🔬

👉 buff.ly/q8aQ75D